FibroGen, Inc. is a San Francisco-based biopharmaceutical company focused on developing innovative therapies targeting chronic kidney disease and fibrotic diseases. Leveraging its proprietary technology platforms, FibroGen aims to deliver novel therapeutics that meet significant unmet medical needs and improve patient outcomes. The company's strong pipeline, supported by cutting-edge research and strategic partnerships, positions it for growth as it seeks to transform healthcare solutions for patients globally. With a commitment to innovation and patient-centric care, FibroGen is poised to make a meaningful impact in the biopharmaceutical landscape. Show more

Location: 350 BAY STREET, SAN FRANCISCO, CA, UNITED STATES, 94133, San Francisco, CA, 94133, USA | Website: https://www.fibrogen.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

39.28M

52 Wk Range

$4.85 - $21.94

Previous Close

$9.02

Open

$9.23

Volume

31,124

Day Range

$9.23 - $9.75

Enterprise Value

82.77M

Cash

118M

Avg Qtr Burn

-1.847M

Insider Ownership

1.66%

Institutional Own.

28.01%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Roxadustat (ROW) Details Chronic kidney disease, Anemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Roxadustat Details Chemotherapy Induced Anemia	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Roxadustat Details Myelodysplastic syndrome, Anemia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FG-3246 (ADC) Details Cancer, Castration-resistant prostate cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FG-3180 (CD46 PET Tracer) Details Metastatic Castration-Resistant Prostate Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FG-3246+ enzalutamide Details Cancer, Castration-resistant prostate cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FG-3165 Details Cancer, Solid tumor/s	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pamrevlumab Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pamrevlumab Details Duchenne muscular dystrophy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pamrevlumab Details Pancreatic cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pamrevlumab Details COVID-19, Infectious disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pamrevlumab Details Cancer, Pancreatic cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Roxadustat (U.S.) Details Anemia, Chronic kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.